X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3151) 3151
Book Review (833) 833
Publication (157) 157
Book Chapter (55) 55
Conference Proceeding (12) 12
Magazine Article (3) 3
Data Set (2) 2
Dissertation (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2367) 2367
humans (2192) 2192
female (1315) 1315
male (1217) 1217
middle aged (883) 883
risk factors (814) 814
thromboembolic events (784) 784
aged (771) 771
adult (676) 676
cardiac & cardiovascular systems (613) 613
thromboembolism (590) 590
thrombosis (550) 550
thromboembolic complications (528) 528
hematology (471) 471
stroke (456) 456
anticoagulants - therapeutic use (417) 417
peripheral vascular disease (415) 415
risk (411) 411
atrial fibrillation (407) 407
surgery (397) 397
treatment outcome (392) 392
abridged index medicus (388) 388
anticoagulants (363) 363
thromboembolic disease (348) 348
retrospective studies (345) 345
care and treatment (301) 301
aged, 80 and over (299) 299
adolescent (292) 292
pulmonary embolism (289) 289
venous thromboembolism (284) 284
incidence (274) 274
medicine & public health (274) 274
warfarin (273) 273
prevention (271) 271
anticoagulation (269) 269
venous thromboembolic disease (265) 265
deep-vein thrombosis (252) 252
risk-factors (251) 251
medicine, general & internal (238) 238
molecular-weight heparin (230) 230
chronic thromboembolic pulmonary hypertension (227) 227
management (220) 220
analysis (219) 219
child (219) 219
prospective studies (219) 219
thromboembolism - etiology (219) 219
mortality (218) 218
therapy (217) 217
clinical neurology (210) 210
oncology (205) 205
diagnosis (204) 204
risk assessment (195) 195
venous thrombosis (192) 192
cancer (190) 190
follow-up studies (186) 186
prevalence (180) 180
respiratory system (175) 175
thromboembolism - prevention & control (174) 174
thromboembolic risk (173) 173
disease (172) 172
anticoagulants - administration & dosage (170) 170
pulmonary-embolism (169) 169
young adult (168) 168
anticoagulants - adverse effects (165) 165
cardiology (163) 163
health aspects (162) 162
complications (160) 160
pulmonary hypertension (157) 157
child, preschool (155) 155
deep venous thrombosis (155) 155
time factors (154) 154
patients (152) 152
aspirin (146) 146
atrial fibrillation - complications (146) 146
hypertension (145) 145
prognosis (144) 144
internal medicine (143) 143
transesophageal echocardiography (143) 143
animals (141) 141
pediatrics (141) 141
research (139) 139
thrombosis - etiology (138) 138
children (135) 135
pharmacology & pharmacy (133) 133
venous thrombosis - etiology (131) 131
drug therapy (129) 129
pregnancy (128) 128
prophylaxis (127) 127
cardiovascular (126) 126
medical research (123) 123
antithrombotic therapy (121) 121
follow-up (121) 121
orthopedics (120) 120
chronic disease (119) 119
safety (119) 119
thromboembolism - epidemiology (119) 119
health risk assessment (118) 118
chemotherapy (117) 117
complications and side effects (115) 115
coagulation (113) 113
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2967) 2967
French (93) 93
German (71) 71
Spanish (48) 48
Russian (11) 11
Portuguese (8) 8
Polish (7) 7
Hungarian (4) 4
Italian (3) 3
Korean (2) 2
Chinese (1) 1
Croatian (1) 1
Czech (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American Heart Association, ISSN 2047-9980, 07/2017, Volume 6, Issue 7, p. n/a
Background-Increasing age predisposes to both thromboembolic and bleeding events in patients with atrial fibrillation; therefore, balancing risks and benefits... 
atrial fibrillation | thromboembolic events | major bleeding | very elderly | anticoagulation | DEFINITION | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | STROKE PREVENTION | OLDER | TRIAL | THERAPY | WARFARIN | ORAL ANTICOAGULANTS | NET CLINICAL BENEFIT | AGE | Age Factors | Anticoagulants - administration & dosage | Humans | Stroke - diagnosis | Hemorrhage - mortality | Male | Ischemic Attack, Transient - diagnosis | Incidence | Patient Selection | Thromboembolism - diagnosis | Fibrinolytic Agents - adverse effects | Ischemic Attack, Transient - prevention & control | Thromboembolism - prevention & control | Time Factors | Atrial Fibrillation - mortality | Clinical Decision-Making | Ischemic Attack, Transient - etiology | Platelet Aggregation Inhibitors - administration & dosage | Aged, 80 and over | Female | Registries | Stroke - mortality | Atrial Fibrillation - diagnosis | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Risk Assessment | Administration, Oral | Atrial Fibrillation - drug therapy | Europe | Risk Factors | Atrial Fibrillation - complications | Treatment Outcome | Thromboembolism - etiology | Thromboembolism - mortality | Ischemic Attack, Transient - mortality | Anticoagulants - adverse effects | Stroke - etiology | Aged | Fibrinolytic Agents - administration & dosage | Hemorrhage - chemically induced | Index Medicus
Journal Article
Journal Article
Stroke, ISSN 0039-2499, 08/2016, Volume 47, Issue 8, pp. 2031 - 2037
Journal Article
Circulation Journal, ISSN 1346-9843, 07/2019, Volume 83, Issue 8, pp. 1747 - 1754
Background: There is limited information about the clinical profiles of patients with hypertrophic cardiomyopathy (HCM) and thromboembolic events in a... 
DIAGNOSIS | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | Atrial fibrillation | RISK | CHADS score | ATRIAL-FIBRILLATION | STROKE | Thromboembolic events | IMPACT | TASK-FORCE | ORAL ANTICOAGULANTS | Hypertrophic cardiomyopathy | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 11/2018, Volume 13, Issue 11, pp. e0207218 - e0207218
Thrombotic manifestations are a hallmark of many auto-immune diseases (AID), specially of warm autoimmune hemolytic anemia (wAIHA), as 15 to 33% of adults with... 
HEALTH-ORGANIZATION CLASSIFICATION | CRITERIA | SYSTEMIC-LUPUS-ERYTHEMATOSUS | THROMBOTIC COMPLICATIONS | DISEASES | NEOPLASMS | PADUA PREDICTION SCORE | MULTIDISCIPLINARY SCIENCES | RISK | 2016 REVISION | PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA | Multivariate Analysis | Humans | Middle Aged | Risk Factors | Anticoagulants - therapeutic use | Male | Anemia, Hemolytic, Autoimmune - complications | Anemia, Hemolytic, Autoimmune - blood | Venous Thromboembolism - blood | Venous Thromboembolism - etiology | Venous Thromboembolism - prevention & control | Bilirubin - blood | Anemia, Hemolytic, Autoimmune - therapy | Adult | Female | Aged | Leukocyte Count | Retrospective Studies | Complications and side effects | Hemolytic anemia | Physiological aspects | Development and progression | Genetic aspects | Research | Diagnosis | Antiphospholipid antibodies | Thromboembolism | Risk factors | Laboratories | Multiple myeloma | Antibodies | Bilirubin | Multivariate analysis | Medical diagnosis | Blood | Splenectomy | Immunology | Autoimmune hemolytic anemia | Hemoglobin | Lupus | Anticoagulants | Immunoglobulins | Internal medicine | Anemia | Risk analysis | Patients | Thrombosis | Disease prevention | Medicine | Hospitals | Medical prognosis | Predictions | Adults | Health risk assessment | Tumors | Index Medicus | Life Sciences | Human health and pathology
Journal Article
Immunologic Research, ISSN 0257-277X, 12/2018, Volume 66, Issue 6, pp. 668 - 674
Journal Article
Journal Article
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2016, Volume 139, Issue 5, pp. 1489 - 1495.e5
Abstract Background EXCELS was a postmarketing commitment to the US Food and Drug Administration to assess long-term safety of omalizumab in an observational... 
Allergy and Immunology | arterial thromboembolic event | safety | serious adverse event | Adverse event | clinical trials | omalizumab | moderate to severe asthma | EXHALED BREATH CONDENSATE | GLUCOCORTICOIDS | RISK | SEVERE ALLERGIC-ASTHMA | IMMUNOLOGY | ADULT-ONSET ASTHMA | ALLERGY | ANTIIMMUNOGLOBULIN-E THERAPY | SEVERE PERSISTENT ASTHMA | ACUTE MYOCARDIAL-INFARCTION | CORONARY-HEART-DISEASE | ANTI-IGE ANTIBODY | Anti-Asthmatic Agents - adverse effects | Prospective Studies | Omalizumab - adverse effects | Anti-Asthmatic Agents - therapeutic use | Humans | Middle Aged | Male | Asthma - drug therapy | Incidence | Cardiovascular Diseases - epidemiology | Product Surveillance, Postmarketing | Adult | Female | Omalizumab - therapeutic use | Cerebrovascular Disorders - epidemiology | Asthma - epidemiology | Health maintenance organizations | Pharmaceutical industry | Asthma in children | Stroke (Disease) | Thromboembolism | Analysis | Asthma | Myocardial infarction | Heart | Corticoids | C-reactive protein | Glucocorticoids | Adjudication | Cardiovascular disease | Risk factors | Cerebrovascular system | Motivation | Condensates | Flutter | Chronic obstructive pulmonary disease | Diagnosis | Cross sections | Emergency medical services | Cerebral infarction | Corticosteroids | Mortality | Assessments | Patients | Thrombosis | Quality of life | Side effects | Rheumatoid arthritis | Arteriosclerosis | Monoclonal antibodies | Death | Skin | Cardiovascular diseases | Circulation | Health care | Intervention | Transient ischemic attack | Identification methods | Congenital defects | Medical services | Clinical trials | Immunoglobulin E | Population studies | Arthritis | Malignancy | Angina | Congestive heart failure | Hemorrhage | Risk assessment | Safety engineering | Atherosclerosis | Patient safety | Safety | Drug therapy | Age | Cardiovascular system | Hypertension | Stroke | Statistical analysis | Complications | Hypersensitivity | Diabetes mellitus | Coronary artery disease | Ventricle | Respiration | Pharmaceuticals | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
14.